Related Experiment Video
Updated: Aug 23, 2025

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Shih Chieh Chang1, Pooja Gopal1, Shuhui Lim1
1Quantitative Biosciences, MSD, Singapore 119077, Singapore.
Abstract:
Biodegraders are targeted protein degradation constructs composed of mini-proteins/peptides linked to E3 ligase receptors. We gained deeper insights into their utility by studying Con1-SPOP, a biodegrader against proliferating cell nuclear antigen (PCNA), an oncology target. Con1-SPOP proved pharmacologically superior to its stoichiometric (non-degrading) inhibitor equivalent (Con1-SPOPmut) as it had more potent anti-proliferative effects and uniquely induced DNA damage, cell apoptosis, and necrosis. Proteomics showed that PCNA degradation gave impaired mitotic division and mitochondria dysfunction, effects not seen with the stoichiometric inhibitor. We further showed that doxycycline-induced Con1-SPOP achieved complete tumor growth inhibition in vivo. Intracellular delivery of mRNA encoding Con1-SPOP via lipid nanoparticles (LNPs) depleted endogenous PCNA within hours of application with nanomolar potency. Our results demonstrate the utility of biodegraders as biological tools and highlight target degradation as a more efficacious approach versus stoichiometric inhibition. Once in vivo delivery is optimized, biodegraders may be leveraged as an exciting therapeutic modality.
Insights
Biodegraders offer a superior therapeutic approach by degrading target proteins like PCNA, unlike traditional inhibitors. This targeted protein degradation demonstrated potent anti-cancer effects and complete tumor inhibition in vivo.
Area of Science:
- Molecular Biology
- Oncology
- Biotechnology
Background:
- Biodegraders are novel protein degradation constructs.
- Proliferating cell nuclear antigen (PCNA) is a key oncology target.
- Targeted protein degradation offers a potential therapeutic advantage over inhibition.
Purpose of the Study:
- To investigate the efficacy of Con1-SPOP, a biodegrader targeting PCNA.
- To compare the effects of biodegrader-mediated PCNA degradation with stoichiometric inhibition.
- To evaluate the in vivo therapeutic potential of biodegraders.
Main Methods:
- Utilized Con1-SPOP, a biodegrader targeting PCNA.
- Compared Con1-SPOP with its stoichiometric inhibitor (Con1-SPOPmut).
- Assessed anti-proliferative effects, DNA damage, apoptosis, and necrosis.
- Employed proteomics to analyze downstream effects of PCNA degradation.
- Evaluated in vivo tumor growth inhibition and mRNA delivery via lipid nanoparticles (LNPs).
Main Results:
- Con1-SPOP exhibited superior anti-proliferative effects compared to Con1-SPOPmut.
- PCNA degradation induced DNA damage, apoptosis, and necrosis.
- Proteomics revealed impaired mitotic division and mitochondria dysfunction due to PCNA degradation.
- Doxycycline-induced Con1-SPOP achieved complete tumor growth inhibition in vivo.
- LNP-delivered mRNA encoding Con1-SPOP rapidly depleted endogenous PCNA with nanomolar potency.
Conclusions:
- Biodegraders represent a powerful tool for biological research and therapy.
- Targeted protein degradation is a more efficacious strategy than stoichiometric inhibition.
- Biodegraders hold promise as a future therapeutic modality upon optimization of in vivo delivery.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity
Abnormal Proliferation

